An experimental mRNA vaccine for lung cancer has shown early promise when given before surgery, with no living cancer found in the removed tumours of some patients. Results presented in September 2026 covered 20 people with operable stage two or three non-small-cell lung cancer who received BioNTech’s BNT116 vaccine with the immunotherapy drug cemiplimab and chemotherapy before their operations. Scans showed a partial response in 65 percent of patients, and none saw their cancer progress before surgery. Of the 15 patients whose removed tissue could be assessed, eight had a major pathological response, including six with no viable cancer detected at all. Immune responses against at least one vaccine target were seen in eight of the 12 patients tested. BNT116 is not personalised: it contains six strands of messenger RNA encoding proteins commonly found on lung cancer cells. Side effects were common, with fever in 80 percent and chills in 70 percent, but surgery was not delayed and there were no deaths from treatment.
What the Evidence Shows
Lung cancer is the most common cause of cancer death worldwide, and most patients are diagnosed when the disease is already advanced, so a vaccine that helps before surgery would be a significant advance. The trial, known as LuCa-MERIT-1, is still recruiting and has raised its planned enrolment to 320 patients across seven countries, including Britain, Germany, Spain, Poland and Hungary. A separate randomised phase two trial is now testing the vaccine more rigorously. Caution is needed: the results come from a small group with no comparison arm, so they cannot yet separate the vaccine’s contribution from the chemotherapy and immunotherapy given alongside it, and the median follow-up of 14.5 months is too short to show whether the early responses translate into longer survival. Even so, researchers say the findings justify larger trials. Reporting and analysis from sources such as National Institutes of Health track the same developments, and specialists following BioNTech’s BNT116 lung cancer vaccine say the direction is now consistent across independent lines of evidence.
The Wider Context
The wider context is a health system trying to move from treating illness late to preventing it early, against budgets that reward the opposite. Evidence around BioNTech’s BNT116 lung cancer vaccine is being weighed by guideline committees that ask two questions in order: does it work, and can ordinary services actually deliver it at scale. Many good ideas pass the first test and stall on the second.
What Happens Next
What happens next for BioNTech’s BNT116 lung cancer vaccine depends on the slow machinery of guidelines, funding and training catching up with the evidence. Patients asking about it today should expect honest answers that include uncertainty, and clinicians say a service that explains what is not yet known earns more trust than one that oversells. The research pipeline, at least, is moving in the right direction. You can follow related developments in our coverage of health.
None of this will be settled by a single announcement, study or product launch. The pattern to watch is accumulation: independent confirmations, honest reporting of failures and steady improvement in the underlying numbers. Readers who follow those signals, rather than the loudest claim of the week, will understand this subject better than most of the commentary surrounding it suggests is possible.